key: cord-0697575-x12b5pf0
authors: van Dam, P.A.; Debie, Y.; Teuwen, L.; Verbruggen, L.; Vanhoutte, G.; Peeters, B.; Croes, L.; Vulsteke, C.; Anguille, S.; Vandamme, T.; Peeters, M.
title: Comparison of S1 antibody titers between BNT162b2 and ChAdOx1 COVID-19 vaccination in cancer patients
date: 2022-02-07
journal: ESMO Open
DOI: 10.1016/j.esmoop.2022.100414
sha: 269d4f2fcb01715c9c8b744997047ea045379d1b
doc_id: 697575
cord_uid: x12b5pf0

nan

Patients with cancer who develop SARS-CoV-2 infections are susceptible to severe outcomes and were prioritized during the COVID-19 vaccination strategy 1 . However, low antibody responses have been reported after BNT162b2 vaccination in cancer patients, but still higher as compared to the ChadOx1 vaccination consistent with the modestly reduced effectiveness of the ChadOx1 vaccine in the general population 2,3 . However, a 12-week extended interval was used for the BNT162b2. This study is the first to report differences in the humoral response 28 days post-booster dose in cancer patients vaccinated with either BNT162b2 (Pfizer-BioNTech) or ChAdOx1 (AstraZeneca) following the vaccine interval recommendations of the World Health Organization (WHO).

Blood samples pre-priming and 28 days post-second dose were collected from patients included in the prospective B-VOICE (EudraCT 2021-000300-38) and Tri-VOICE plus (EudraCT 2021-003573-58) studies. Priming and booster dose were administered with an interval of 21 days ± 2 days for 95% and 24-27 days for 5% of the subjects for BNT162b2 and 12 weeks ± 10 days for 90% and 8-10 weeks for 10% of the subjects for ChAdOx1 vaccination. Subjects with a solid tumor (77.7%) were divided into three treatment cohorts: chemotherapy, immunotherapy, and targeted/hormonal therapy. A differentiation for hematologic patients (19.7%) was made between patients receiving rituximab and patients who have undergone hematopoietic stem cell transplantation (HSCT) more than one year ago. Therapy cohorts were based on the type of anti-neoplastic treatment the patients received at time of priming dose. Anti-S1 antibody titers were tested using the Siemens Healthineers Atellica IM SARS-CoV-2 IgG (sCOVG) assay pre-priming and 28 days post-booster (Suppl. Figure 1A , Table 1 ). The differences remained present after exclusion of 22 participants (6.4%) with detectable prepriming antibody titers. Subanalysis showed significantly lower post-booster antibody titers after ChAdOx1 compared to BNT162b2 vaccination in patients receiving immunotherapy ( In contrast, antibody titers were not significantly different between both vaccine types in patients receiving chemotherapy nor in hematologic patients ( Figure 1B ).

While both BNT126b2 and ChAdOx1 vaccines elicit a clear antibody response, dual-dose BNT162b2 elicits higher anti-S1 antibody levels compared to dual-dose ChAdOx1 vaccination in our cancer population. However, this observation does not necessarily translate into reduced protection after ChAdOx1 as no correlate of protection has yet been defined. Significant differences between antibody responses after dual dose BNT162b2 and ChAdOx1 vaccination were seen in patients receiving targeted/hormonal therapy and immunotherapy but not in other treatment cohorts. Hence, it is unsure how these differences might affect cellular immunity and neutralizing antibody titers against the Wuhan SARS-CoV-2 strain and the different occurring SARS-CoV-2 variants. However, given the additional value of the administration of a third vaccination dose in cancer patients, as shown in recent studies, a third dose of BNT162b2 after full ChAdOx1 vaccination might be prioritized in cancer patients 4,5 . J o u r n a l P r e -p r o o f Legend Figure 1 : Humoral immune response 28 days post-booster dose in cancer patients vaccinated with the BNT162B2 or ChAdOx1 vaccine. Violin plots of log-transformed SARS-COV-2 anti-S1 IgG antibody titers 28 days after booster dose in the entire study population (panel A) and in different treatment cohorts (panel B). Inside each violin plot, the geometric mean titers (GMT) is depicted as a point. Anti-S1 IgG-class antibody titers were quantified using a SARS-CoV-2 Immunoassay, Siemens Healthineers Atellica IM SARS-CoV-2 IgG (sCOVG) assay for the detection of antibodies (units/mL). The measuring interval is 1.00-750.00 U/mL, values below this interval were imputed to 1.00U/mL, values above this interval were imputed to 1000U/mL with dotted line indicating LLQ and ULQ, respectively.

J o u r n a l P r e -p r o o f Violin plots of log-transformed SARS-COV-2 anti-S1 IgG antibody titers 28 days after booster dose in the entire study population (panel A) and in different treatment cohorts (panel B). Inside each violin plot, the geometric mean titers (GMT) is depicted as a point. Anti-S1 IgG-class antibody titers were quantified using a SARS-CoV-2 Immunoassay, Siemens Healthineers Atellica IM SARS-CoV-2 IgG (sCOVG) assay for the detection of antibodies (units/mL). The measuring interval is 1.00-750.00 U/mL, values below this interval were imputed to 1.00U/mL, values above this interval were imputed to 1000U/mL with dotted line indicating LLQ and ULQ, respectively.

The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate

Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study

Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Cancer patients

Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses

We are grateful to the B-VOICE and Tri-VOICE plus study teams for patient inclusion and sample collection. They were not compensated for their contribution. We also want to thank all our patients for study participation.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

None declared J o u r n a l P r e -p r o o f